Avacta Group PLC – AVCT – Update on Affimer® Therapy for COVID-19 Infection
Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that collaborative work with the Centre for Virus Research at the University of Glasgow has shown that...
Read More